Stock SRX SIRTEX MEDICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Sirtex Medical Limited Share Price

Equities

SRX

AU000000SRX1

Biotechnology & Medical Research

End-of-day quote Australian S.E.
Other stock markets
 		5-day change 1st Jan Change
- AUD -.--% Intraday chart for Sirtex Medical Limited +2.16% +103.09%
04-15 Sierra Rutile Tells Shareholders to Reject PRM Services' Takover Bid MT
04-12 Euroz Hartleys Adjusts Sierra Rutile Holdings’ Price Target to AU$0.15 From AU$0.12, Keeps at Speculative Buy MT

Chart Sirtex Medical Limited

Dynamic Chart

Latest news about Sirtex Medical Limited

Sierra Rutile Tells Shareholders to Reject PRM Services' Takover Bid MT
Euroz Hartleys Adjusts Sierra Rutile Holdings’ Price Target to AU$0.15 From AU$0.12, Keeps at Speculative Buy MT
Sierra Rutile Holdings Study Shows 11% Reduced Capex to $301 Million, $408 Million NPV, 27.8% IRR MT
Sierra Rutile Tells Shareholders to Reject RPM Services' Takeover Bid MT
Sierra Rutile Reports Lower Capex for Sierra Leone Rutile Project MT
Australian Shares Inch Down as Metal Prices Retreat Amid Stronger US Dollar MT
Sierra Rutile Jumps 31% Following Takeover Offer from PRM Services MT
Sierra Rutile Holdings Receives AU$0.095 Per Share Takeover Bid From PRM Services MT
Sierra Rutile Falls 3% Amid 2023 Loss Swing, Workforce Redundancy Program MT
Sierra Rutile Falls to 2023 Loss per Share of $0.0473 as Revenue Falls 31% MT
Sierra Rutile Posts FY23 Revenue Down 31% to $176.3 Million; Loss of $0.0473 MT
Sierra Rutile Gets Environmental Approval for Sierra Leone Rutile Project MT
Sierra Rutile Holdings Announces Suspension of Area 1 Operations in Sierra Leoe MT
Sierra Rutile Expects No Bulk Sales in Q1 2024 MT
Sierra Rutile Confirms Power Restoration at Sierra Leone Operation MT
More news

Analyst Recommendations on Sirtex Medical Limited

Euroz Hartleys Adjusts Sierra Rutile Holdings’ Price Target to AU$0.15 From AU$0.12, Keeps at Speculative Buy MT
More recommendations

Press releases Sirtex Medical Limited

Morgans rates SRX as Add AQ
ASX-listed Sierra Rutile reports reduced production at Sierra Leone operations AQ
Magle Chemoswed : enters collaboration with Sirtex Medical AQ
Sirtex Medical : reaches milestone 100,000th patient dose delivery of SIR-Spheres® Y-90 resin microspheres PU
Sirtex Medical : New Analysis Reveals First-Line Treatment Data on SIR-Spheres® Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer PU
More press releases

Managers and Directors - Sirtex Medical Limited

Managers TitleAgeSince
Kevin R. Smith CEO
 Chief Executive Officer - -
Amy Pan DFI
 Director of Finance/CFO - 30/09/19
Catherine Parham CTO
 Chief Tech/Sci/R&D Officer - 31/12/21
Members of the board TitleAgeSince
Chao Zhou BRD
 Director/Board Member 34 31/12/17
Matt Schmidt
- -
More insiders

Company Profile

More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SRX Stock